**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 86325

**Manuscript Type:** CASE REPORT

**Co-infectionof *Chlamydia psittaci* and *Tropheryma whipplei*: A case report**

Du ZM *et al*. *Chlamydia psittaci* and *Tropheryma whipplei* co-infection

Zhu-Man Du, Pei Chen

**Zhu-Man Du, Pei Chen,** Respiratory and Critical Care Discipline, Clinical Medicine College, Affiliated Hospital of Chengdu University, Chengdu 610000, Sichuan Province, China

**Author contributions:** Du ZM contributed to manuscript writing and editing, and data collection; Cheng P contributed to conceptualization and supervision; all authors have read and approved the final manuscript.

**Corresponding author: Pei Chen, MBChB, Associate Professor,** Respiratory and Critical Care Discipline, Clinical Medicine College, Affiliated Hospital of Chengdu University, No. 82 North Section 2, Second Ring Road, Chengdu 610000, Sichuan Province, China. 1552156159@qq.com

**Received:** June 19, 2023

**Revised:** August 15, 2023

**Accepted:** September 25, 2023

**Published online:** October 16, 2023

**Abstract**

BACKGROUND

The co-infection of *Chlamydia psittaci* (*C. psittaci*) and *Tropheryma whipplei* (*T. whipplei*) is unusual, and the detection of pathogenic microorganisms is particularly important for patients with severe diseases or poor experience in treatment. Early identification of pathogens can significantly improve the prognosis of the patients. Targeted next-generation sequencing (tNGS) is currently widely used in clinical practice for various infectious diseases, including respiratory infections, to achieve early, accurate, and rapid microbial diagnosis.

CASE SUMMARY

We report a case of a 40-year-old female patient with a history of contact with parrots who was diagnosed with *C. psittaci* and *T. whipplei* infection through bronchial lavage fluid targeted next generation sequencing. After moxifloxacin treatment, the patient's symptoms improved significantly, and the imaging changes were obviously resolved.

CONCLUSION

Coinfection with *C. psittaci* and *T. whipplei* is not common. In this case, timely and accurate identification of both pathogens was achieved using tNGS. Moreover, the efficacy of monotherapy with moxifloxacin was confirmed.

**Key Words:** Infectious diseases; *Chlamydia psittaci*; *Tropheryma whipplei*; Targeted next generation sequencing; Case report

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Du ZM, Chen P. Co-infection of *Chlamydia psittaci* and *Tropheryma whipplei*: A case report. *World J Clin Cases* 2023; 11(29): 7144-7149

**URL:** <https://www.wjgnet.com/2307-8960/full/v11/i29/7144.htm>

**DOI:** https://dx.doi.org/10.12998/wjcc.v11.i29.7144

**Core Tip:** The co-infection of *Chlamydia psittaci* and *Tropheryma whipplei* is not common. Due to its ability to cause severe infections, timely and reliable diagnosis is crucial for improving prognosis. In recent years, the development of targeted next-generation sequencing has made the diagnosis of pathogenic microorganisms more economical and efficient.

**INTRODUCTION**

Psittacosis is a zoonotic infectious disease caused by *Chlamydia psittaci* (*C. psittaci*), which is a gram-negative bacterium belonging to the *Chlamydia spp*. This pathogen mainly parasitizes parrots, pigeons, poultry, *etc.* Humans are mainly affected by direct contact with birds and poultry excrement and respiratory secretions. Handling the feathers, tissues, or corpses of infected birds also carries a risk of infection[1]. The first description of psittacosis in the medical literature was in 1879[2], and according to subsequent reports, psittacosis may be the cause of one percent of cases among community-acquired pneumonia[3]. Clinical manifestations of psittacosis vary from asymptomatic infection to severe systemic symptoms and may even lead to fatal systemic illness. Symptoms of infected individuals may include headache, chills, fever (even high fever), myalgia, and dry cough during the course of the disease, which may be accompanied by dyspnoea and chest tightness[4]. *Tropheryma whipplei* (*T. whipplei*) is a gram-positive bacterium first described by American pathologist George Hoyt Whipple in 1907 and belongs to the trophozoite genus[5]. The most obvious symptoms include arthralgia, diarrhoea, abdominal pain, and weight loss, and reports of endocarditis, nervous system infection, uveitis, arthritis and osteoarthritis infection can also be seen[6]. However, there are few reports about pneumonia caused by *T. whipplei*. A previous study found that the respiratory infection rate was only 13%-14%[7], of which only approximately 30% of patients had respiratory symptoms[8], but the symptoms were not typical and included dyspnoea, cough, chest pain, and vital capacity reduction[9]. Reports of coinfection of *C. psittaci* and *T. whipplei* are extremely rare, but due to their ability to cause severe infections, rapid progression, and life-threatening conditions, timely and reliable diagnosis is crucial for treatment.

In recent years, high-throughput sequencing methods have developed rapidly, mainly including whole genome sequencing (WGS), metagenomic next-generation sequencing (mNGS), and targeted next-generation sequencing (tNGS). Among them, WGS is less directly applied in clinical practice and is generally used in epidemiological investigations and research on the evolution of drug-resistant strains. MNGS can detect all pathogens in the sample without discrimination, while tNGS mainly focuses on common infectious pathogens in clinical practice. TNGS designs specific primers, uses a super multiplex polymerase chain reaction (PCR) library system to target and amplify the target sequence, and then uses high-throughput sequencing for synchronous detection of amplification products, achieving a new method of broad-spectrum accurate detection of pathogens. In this report, tNGS was used to confirm the clinical rarity of pneumonia caused by *C. psittaci* and *T. whipplei*.

**CASE PRESENTATION**

***Chief complaints***

A 40-year-old female patient was admitted to the hospital for fever on November 6, 2022.

***History of present illness***

The patient had a fever for 10 d and a maximum body temperature of 39.6°C, accompanied by dizziness and headache, but she had no other symptoms, such as cough, abdominal pain, or diarrhea.

***History of past illness***

The patient had previously been physically fit, but she had bought three parrots one week before the onset of symptoms, one of which was sick.

***Personal and family history***

The patient had no special history of personal history or family history.

***Physical examination***

On examination, body temperature was 36.0°C; heart rate was 94 beats/min; respiratory rate was 21 breaths/min; blood pressure was 100/72 mmHg; and pulse oxygen saturation was 96%. The patient was well built and cooperative, had no pharyngeal hyperaemia, and had no enlargement or purulent discharge of the tonsils. Breath sounds in both lungs were rough, and moist rales could be heard in the lower lobe of the right lung. Heart and abdominal examinations showed no significant findings.

***Laboratory examinations***

A preliminary hematological examination (Table 1) showed that the hypersensitive C-reactive protein was significantly increased, transaminase and direct bilirubin were slightly increased, and electrolyte metabolism was deranged. The white blood cells and their respective classification ratios were normal, and procalcitonin was normal. In addition, during coronavirus disease 2019 (COVID-19), we tested the patient for COVID-19 nucleic acid, and the results were negative.

***Imaging examinations***

A computed tomography (CT) scan on November 6, 2022 (Figure 1A-C) revealed multiple large uneven ground glass shadows in the lower lobe of the right lung, with grid shadows visible inside, close to the pleura, and special pathogen infections could not be ruled out.

**FINAL DIAGNOSIS**

The patient received fiber bronchoscopy examination, and fiber bronchoscopy reached the lower lobe bronchus of the right lung. The lower lobe bronchus of the right lung was repeatedly irrigated. The collected samples were then sent to the laboratory for tNGS testing and analysis, which revealed *C. psittaci* and *T. whipplei* infection.

**TREATMENT**

The patient was treated with moxifloxacin 0.4 g once daily for 10 d.

**OUTCOME AND FOLLOW-UP**

During hospitalization, the patient experienced coughing, phlegm, and diarrhea. Following treatment, the body temperature returned to normal, and the above symptoms disappeared completely. Hypersensitive C-reactive protein, transaminase and direct bilirubin returned to normal values. After 10 d of anti-infection treatment with moxifloxacin, a CT scan on November 16, 2022 (Figure 1D-F) showed that patch shadows and ground glass shadows in the right lower lobe lesions were obviously resolved. After discharge, the patient insisted on taking moxifloxacin orally for one week, but she was unwilling to undergo a recheck chest CT again for a review as her physical condition was good.

**DISCUSSION**

This article reports a rare case of co-infection caused by *C. psittaci* and *T. whipplei*. There are no specific clinical manifestations of psittacosis, and routine detection methods lack sensitivity and specificity, making it difficult to determine the epidemiology of psittacosis. Before 2013, some literature mentioned the occurrence of psittacosis cases, but with the increasing number of poultry raised in households and farms, large-scale outbreaks of psittacosis have frequently occurred, especially since 2020. The majority of transmission modes of psittacosis are limited to human exposure to contaminated birds and their excreta. However, some literature has reported the possibility of human-to-human transmission, and there is no definitive conclusion on whether there is human-to-human transmission in the second and third generations[4]. The diagnosis and treatment of Whipple's disease in the digestive system is relatively mature, but reports of infection in the respiratory system are rare. In addition, strong evidence shows that *T. whipplei* is a pathogen of acute pneumonia. Previous studies have found that *T. whipplei* is detected in the alveolar lavage fluid of patients with immune deficiency and patients with pneumonia who were admitted to intensive care units[10,11]. This evidence strongly supports a link between *T. whipplei* and pulmonary infection. It is noteworthy that *T. whipplei* can also exist in the saliva of asymptomatic patients[12], who inhale pathogenic bacteria from the mouth, leading to pneumonia[13]. In this case, the patient had a clear history of contact with sick parrots, with fever symptoms initially appearing and headache and respiratory symptoms gradually developing during the course of the disease. Hematological examination showed that the hypersensitive C-reactive protein was significantly increased, and transaminase and direct bilirubin were slightly increased. These symptoms and examinations are consistent with psittacosis and *T. whipplei* pneumonia, and tNGS testing confirmed the presence of *C. psittaci* and *T. whipplei* in the alveolar lavage fluid.

In clinical practice, traditional microbial culture methods and empirical diagnosis are still the mainstream, and the efficiency of traditional pathogen diagnosis methods is not high. Bacterial cultivation takes a long time, and in clinical practice, it is usually not possible to wait until the pathogenic microorganisms have been reported before taking medication. In addition, the positive rate of microbial culture is relatively low, resulting in many pathogenic infections that cannot obtain microorganisms. The emergence of high-throughput sequencing technology has improved this situation to some extent. At present, a variety of high-throughput sequencing technology have been used for the identification of pathogenic microorganisms in clinical infectious diseases, especially when there is a lack of diagnostic clues, it has significant advantages in identifying pathogenic microorganisms. According to different detection strategies, high-throughput sequencing methods are mainly divided into tNGS, mNGS and WGS. MNGS technology is to directly conduct unbiased detection and sequence analysis of all nucleic acids in the specimen, including but not limited to the detection of pathogenic bacteria nucleic acids, and also includes the nucleic acid detection of other pathogens and a large number of human host cells[14]. Due to the complex and time-consuming data processing of mNGS, it has the characteristics of high cost. In particular, mNGS is greatly influenced by human genes making the results easily misunderstood and interfered with. TNGS is a combination of multiplex PCR amplification and sequencing technology, which can detect dozens to hundreds of common pathogenic microorganisms and their virulence and drug resistance genes in samples. Through targeted amplification, it can improve the reliability of pathogen detection. At the same time, it can also provide personalized medication tips for suspected pathogenic microorganisms according to different infection sites. Because only specific target regions need to be sequenced, data processing and analysis are usually easier, making it faster and more economical. However, as mentioned earlier, due to the high cost and time-consuming nature of mNGS, the clinical application of pathogen metagene sequencing is still limited to a small range, leaving a collaborative space for tNGS. But rather than replacing the application space of mNGS in clinical practice with tNGS, the two complement each other and jointly improve the efficiency of hospital pathogen diagnosis. An article published in 2022 pointed out that there is no significant difference in the detection efficiency of bacteria, fungi, and viruses between mNGS and tNGS, but the removal of human genetic background by tNGS may affect the detection rate of G-negative bacteria, viruses, and intracellular bacteria, leading to higher false-negatives[15].

The guidelines are consistent with the literature recommendations for psittacosis. The first-line medication is tetracyclines, with a duration of at least 7-14 d, and the second choice of antibiotics include azithromycin, clarithromycin, erythromycin, and chloramphenicol[1]. There is not much evidence for the clinical use of quinolones alone. However, there are also studies suggesting that moxifloxacin has an anti-chlamydia effect, and moxifloxacin in this case has shown a good therapeutic effect, so first-line treatment is not used. This case also provides new evidence for the use of quinolones for psittacosis. The drugs for the treatment of *T. whipplei* mainly include penicillin, streptomycin, tetracycline, ceftriaxone, meropenem, compound trimethoprim, doxycycline and hydroxychloroquine. In the past, tetracycline was once listed as a first-line treatment drug, but a high recurrence rate was observed after treatment[16]. However, most of the treatments target digestive disorders caused by *T. whipplei*, and there are few reports on the treatment experience of pneumonia related to Whipple's disease. Therefore, there is still no broad consensus on the treatment of Whipple's disease-related pneumonia, and there is a lack of clinical treatment experience for a large number of cases. The anti-infection treatment plans are all empirical treatments, lacking sufficient evidence support.

**CONCLUSION**

Collectively, we believe that tNGS is promising in the diagnosis of unexplained pneumonia, and quinolones are effective in the treatment of psittacosis and Whipple's disease, which deserves more clinical attention.

**REFERENCES**

1 **Balsamo G**, Maxted AM, Midla JW, Murphy JM, Wohrle R, Edling TM, Fish PH, Flammer K, Hyde D, Kutty PK, Kobayashi M, Helm B, Oiulfstad B, Ritchie BW, Stobierski MG, Ehnert K, Tully TN Jr. Compendium of Measures to Control Chlamydia psittaci Infection Among Humans (Psittacosis) and Pet Birds (Avian Chlamydiosis), 2017. *J Avian Med Surg* 2017; **31**: 262-282 [PMID: 28891690 DOI: 10.1647/217-265]

2 **Khadka S**, Timilsina B, Pangeni RP, Regmi PR, Thapa AS. Importance of clinical history in the diagnosis of psittacosis: A case report. *Ann Med Surg (Lond)* 2022; **82**: 104695 [PMID: 36268359 DOI: 10.1016/j.amsu.2022.104695]

3 **Hogerwerf L**, DE Gier B, Baan B, VAN DER Hoek W. Chlamydia psittaci (psittacosis) as a cause of community-acquired pneumonia: a systematic review and meta-analysis. *Epidemiol Infect* 2017; **145**: 3096-3105 [PMID: 28946931 DOI: 10.1017/S0950268817002060]

4 **Cui Z**, Meng L. Psittacosis Pneumonia: Diagnosis, Treatment and Interhuman Transmission. *Int J Gen Med* 2023; **16**: 1-6 [PMID: 36628298 DOI: 10.2147/IJGM.S396074]

5 **Li W**, Zhang Q, Xu Y, Zhang X, Huang Q, Su Z. Severe pneumonia in adults caused by Tropheryma whipplei and Candida sp. infection: a 2019 case series. *BMC Pulm Med* 2021; **21**: 29 [PMID: 33451316 DOI: 10.1186/s12890-020-01384-4]

6 **Wang S**, Xia D, Wu J, Jia D, Li L, Xu S. Severe Pneumonia Caused by Infection With Tropheryma whipplei Complicated With Acinetobacter baumannii Infection: A Case Report Involving a Young Woman. *Front Public Health* 2021; **9**: 729595 [PMID: 34760862 DOI: 10.3389/fpubh.2021.729595]

7 **Dolmans RA**, Boel CH, Lacle MM, Kusters JG. Clinical Manifestations, Treatment, and Diagnosis of Tropheryma whipplei Infections. *Clin Microbiol Rev* 2017; **30**: 529-555 [PMID: 28298472 DOI: 10.1128/CMR.00033-16]

8 **Kutlu O**, Erhan SŞ, Gökden Y, Kandemir Ö, Tükek T. Whipple's Disease: A Case Report. *Med Princ Pract* 2020; **29**: 90-93 [PMID: 30763942 DOI: 10.1159/000498909]

9 **Dutly F**, Altwegg M. Whipple's disease and "Tropheryma whippelii". *Clin Microbiol Rev* 2001; **14**: 561-583 [PMID: 11432814 DOI: 10.1128/CMR.14.3.561-583.2001]

10 **Bousbia S**, Papazian L, Auffray JP, Fenollar F, Martin C, Li W, Chiche L, La Scola B, Raoult D. Tropheryma whipplei in patients with pneumonia. *Emerg Infect Dis* 2010; **16**: 258-263 [PMID: 20113556 DOI: 10.3201/eid1602.090610]

11 **Lozupone C**, Cota-Gomez A, Palmer BE, Linderman DJ, Charlson ES, Sodergren E, Mitreva M, Abubucker S, Martin J, Yao G, Campbell TB, Flores SC, Ackerman G, Stombaugh J, Ursell L, Beck JM, Curtis JL, Young VB, Lynch SV, Huang L, Weinstock GM, Knox KS, Twigg H, Morris A, Ghedin E, Bushman FD, Collman RG, Knight R, Fontenot AP; Lung HIV Microbiome Project. Widespread colonization of the lung by Tropheryma whipplei in HIV infection. *Am J Respir Crit Care Med* 2013; **187**: 1110-1117 [PMID: 23392441 DOI: 10.1164/rccm.201211-2145OC]

12 **Keita AK**, Raoult D, Fenollar F. Tropheryma whipplei as a commensal bacterium. *Future Microbiol* 2013; **8**: 57-71 [PMID: 23252493 DOI: 10.2217/fmb.12.124]

13 **García-Álvarez L**, Pérez-Matute P, Blanco JR, Ibarra V, Oteo JA. High prevalence of asymptomatic carriers of Tropheryma whipplei in different populations from the North of Spain. *Enferm Infecc Microbiol Clin* 2016; **34**: 340-345 [PMID: 26585816 DOI: 10.1016/j.eimc.2015.09.006]

14 **Wilson MR**, Naccache SN, Samayoa E, Biagtan M, Bashir H, Yu G, Salamat SM, Somasekar S, Federman S, Miller S, Sokolic R, Garabedian E, Candotti F, Buckley RH, Reed KD, Meyer TL, Seroogy CM, Galloway R, Henderson SL, Gern JE, DeRisi JL, Chiu CY. Actionable diagnosis of neuroleptospirosis by next-generation sequencing. *N Engl J Med* 2014; **370**: 2408-2417 [PMID: 24896819 DOI: 10.1056/NEJMoa1401268]

15 **Gaston DC**, Miller HB, Fissel JA, Jacobs E, Gough E, Wu J, Klein EY, Carroll KC, Simner PJ. Evaluation of Metagenomic and Targeted Next-Generation Sequencing Workflows for Detection of Respiratory Pathogens from Bronchoalveolar Lavage Fluid Specimens. *J Clin Microbiol* 2022; **60**: e0052622 [PMID: 35695488 DOI: 10.1128/jcm.00526-22]

16 **Fenollar F**, Ponge T, La Scola B, Lagier JC, Lefebvre M, Raoult D. First isolation of Tropheryma whipplei from bronchoalveolar fluid and clinical implications. *J Infect* 2012; **65**: 275-278 [PMID: 22172770 DOI: 10.1016/j.jinf.2011.11.026]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest to disclose.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** June 19, 2023

**First decision:** August 4, 2023

**Article in press:** September 25, 2023

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Emran TB, Bangladesh; Yeoh SW, Australia **S-Editor:** Lin C **L-Editor:** Ma JY **P-Editor:** Lin C

**Figure Legends**



**Figure 1 Chronological computed tomography of the chest demonstrating changes in the lungs.** A-C: Multiple large uneven ground glass shadows in the lower lobe of the right lung, with grid shadows visible inside, close to the pleura, as shown on a computed tomography on November 6, 2022; D-F: The patchy and ground glass shadows in the lesion of the lower lobe of the right lung were clearly resolved on November 16, 2022.

**Table 1 Results of blood tests on admission**

|  |  |  |
| --- | --- | --- |
| **Blood tests** | **Results** | **Normal range** |
| White blood cells (/L) | 5.78 × 109 | 3.5 × 109-9.5 × 109 |
| Neutrophils (%) | 70.5 | 40.0-75.0 |
| Lymphocytes (%) | 22.2 | 20.0-50.0 |
| Red blood cells (/L) | 4.2 × 1012 | 3.8 × 1012-5.1 × 1012 |
| Haemoglobin (g/L) | 119 | 115-150 |
| Platelets (/L) | 186 × 109 | 125 × 109-350 × 109 |
| Total protein (g/L) | 68.9 | 65.0-85.0 |
| Albumin (g/L) | 42.0 | 40.0-55.0 |
| Total bilirubin (umol/L) | 16.3 | < 23.0 |
| Direct bilirubin (umol/L) | 9.4 | < 6.8 |
| Aspartate aminotransferase (IU/L) | 53 | 13.0-35.0 |
| Alanine aminotransferase (IU/L) | 61 | 7.0-40.0 |
| Lactate dehydrogenase (IU/L) | 431.2 | 120.0-250.0 |
| Creatinine (umol/L) | 48.1 | 41.0-73.0 |
| Sodium (mmol/L) | 128 | 137.0-147.0 |
| Potassium (mmol/L) | 3.08 | 3.5-5.5 |
| Chloride (mmol/L) | 92.4 | 99-110 |
| Hypersensitive C-reactive (mg/L) | 165.75 | 0.5-10 |
| Procalcitonin (ng/mL) | < 0.05 | < 0.5 |
| Prothrombin time (s) | 13.5 | 9-14 |
| Activated partial thromboplastin time (s) | 28.9 | 20-40 |

IU: International unit.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**